Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803462 | 0.89 | CCR3 (0.67) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL6749556 | 0.82 | CCR3 (0.58) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL15140944 | 0.80 | CCR3 (0.73) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL13003723 | 0.80 | CCR3 (0.55) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL8907111 | 0.79 | CCR3 (0.63) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL803083 | 0.79 | CCR3 (0.58) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL544141 | 0.79 | CCR3 (0.67) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL69200 | 0.79 | CCR3 (0.67) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL6749208 | 0.79 | CCR3 (0.54) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL2735346 | 0.78 | CCR3 (0.71) | CCR3ACHEALDH1A1CXCR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
| CN-1708493-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558600-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004037810-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CCR3 458/4885ACHE 1031/4885ALDH1A1 1380/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CCR3 458/4885ACHE 1031/4885ALDH1A1 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.